101376-26-5

Basic information

• Product Name: (R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE
• Synonyms: (R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE;(R)-4-Benzly-3-hydroxymethylmorpholine;(R)-4-Benzyl-3-hydroxymethyloorpholine;(R)-(4-BenzylMorpholin-3-yl)Methanol;[(3R)-4-benzylMorpholin-3-yl]Methanol;(R)-4-(phenylmethyl)-3-Morpholinemethanol;(3R)-4-(Phenylmethyl)-3-morpholinemethanol
• CAS NO: 101376-26-5
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.268880
• Mol File: 101376-26-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 229-230 °C(Solv: ethanol (64-17-5); ethyl ether (60-29-7))
• Boiling Point: 322.7 °C at 760 mmHg
• Flash Point: 149 °C
• Appearance: /
• Density: 1.117 g/cm³
• Vapor Pressure: 0.000113mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: (R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE(101376-26-5)
• EPA Substance Registry System: (R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE(101376-26-5)

Safety Data

• Hazardous Substances Data: 101376-26-5(Hazardous Substances Data)

Usage

General Description

(R)-4-benzyl-3-hydroxymethylmorpholine is a chemical compound that belongs to the morpholine class. It is a morpholine derivative with a benzyl group attached to the fourth carbon and a hydroxymethyl group attached to the third carbon of the morpholine ring. (R)-4-BENZYL-3-HYDROXYMETHYLMORPHOLINE has potential pharmaceutical applications due to its unique structure and properties. It may be used as a building block in the synthesis of various drugs and pharmaceuticals. Additionally, it has shown potential as a chiral auxiliary for asymmetric synthesis. The compound's properties and potential applications make it an interesting target for further study and development in the pharmaceutical and chemical industries.

InChI:InChI=1/C12H17NO2/c14-9-12-10-15-7-6-13(12)8-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2/t12-/m1/s1

Upstream product

• 714971-27-4 (R)-(4-benzylmorpholin-3-yl)methanol hydrochloride 
• 515156-88-4 N-benzyl-D-serine 
• 1266238-73-6 (R)-4-benzyl-5-(hydroxymethyl)morpholin-3-one 
• 1266238-72-5 (R)-4-benzyl-5-((benzyloxy)methyl)morpholin-3-one 
• 1266238-71-4 (S)-2-(benzylamino)-3-(benzyloxy)propan-1-ol 
• 1266238-70-3 N-benzoyl-O-benzyl-D-serine 
• 86808-09-5 N-(p-methylbenzoyl)-D-serine 
• 98-88-4 benzoyl chloride 
• 100-52-7 benzaldehyde 
• 106973-40-4 ethyl (S)-5-oxo-4-(phenylmethyl)morpholine-3-carboxylate 
• 106973-37-9 (3S)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 106910-76-3 (S)-2-(benzylamino)-3-hydroxypropanoic acid 
• 211053-49-5 (R)-3-hydroxymethylmorpholine 
• 100-39-0 benzyl bromide 

Downstream Products

• 681851-29-6 (S)-3-(bromomethyl)-4-(phenylmethyl)morpholine 
• 211053-49-5 (R)-3-hydroxymethylmorpholine 
• 917572-28-2 (S)-4-benzyl-3-(chloromethyl)morpholine 
• 215917-99-0 (R)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 
• 1266238-75-8 (S)-4-benzyl-3-(fluoromethyl)morpholine 
• 917610-12-9 tert-butyl (2-{(3R)-4-[1-(diphenylmethyl)azetidin-3-yl]morpholin-3-yl}ethyl)carbamate 
• 917610-24-3 (2-{(3R)-4-[1-(diphenylmethyl)azetidin-3-yl]morpholin-3-yl}ethyl)amine 
• 917610-10-7 tert-butyl {2-[(3R)-4-benzylmorpholin-3-yl]ethyl}carbamate 
• 917610-09-4 {2-[(3R)-4-benzylmorpholin-3-yl]ethyl}amine 
• 917572-33-9 2-{(3R)-4-[1-(diphenylmethyl)azetidin-3-yl]morpholin-3-yl}ethanol 
• 917572-35-1 {(3R)-4-[1-(diphenylmethyl)azetidin-3-yl]morpholin-3-yl}methanol 
• 917572-30-6 methyl [(3R)-4-benzylmorpholin-3-yl]acetate 
• 917572-31-7 2-[(3R)-4-benzylmorpholin-3-yl]ethanol 
• 917572-29-3 (R)-2-(4-benzylmorpholin-3-yl)acetonitrile 

Relevant articles and documents

-

-

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

NOVEL HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.